Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...
Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR ...
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...
—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a ...
Pharmaceutical Technology on MSN
Insmed receives EC approval for Brinsupri to treat NCFB
"Insmed receives EC approval for Brinsupri to treat NCFB" was originally created and published by Pharmaceutical Technology, ...
Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage[i] — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation — BRINSUPRI Was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback